Sign in to view content

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

Carl D. Regillo, MD

Video
Published 2022

Related

Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
David M. Brown, MD
Updates from the Field
2018
Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the Pegcetacoplan Clinical Program
Diana V Do, MD, FASRS
Updates from the Field
2025
Quantitative Contrast Sensitivity Longitudinal Changes Correlate Better Than Visual Acuity With Geographic Atrophy Progression
John B. Miller, MD
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more